Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 271

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Biologics vs. small molecules: Drug costs and patient access

Open access
Makurvet, Favour Danladi·2021·Medicine in Drug Discovery

Abstract

Significant advances in drug research and development are herein reviewed first to set the background for a critical consideration of the economic sustainability of biologics and small molecules, why biologic drugs are more expensive, and how drug cost often influences patient access to one drug class over the other. Also strongly emphasized is the need for the drug-making, especially the biopharmaceutical, industry to consider a reassignment of priorities so that more patients can enjoy the great benefits that come with blockbuster drugs, many of which are of biological origin but extremely expensive. A balance between the efficacy of wonder-performing drugs and the patient's financial ability to access them must be established to obliterate the crippling effect of the high costs of drugs on the poor majority of patients – those who cannot afford them. The overarching point broadly emphasized is that the actual success in drug discovery and development and in healthcare delivery should be measured not only by the magnitude of scientific breakthroughs but also by the level to which they are affordable to patients as determined by their costs. To enhance patients' access to drugs and new and/or improved healthcare technologies, more research attention must be paid to such cheaper alternatives as small molecules generics, biosimilars, and antibody-drug conjugates; government policies must be established to encourage the commercialization of biosimilars; and pharmaceutical companies must be charitable enough to run assistance programs for eligible financially handicap patients while seeking to make profits from the drug-making business.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.medidd.2020.100075

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 271

Metadata

Authors
Makurvet, F. D.
Venue
Medicine in Drug Discovery
Publisher
Elsevier BV
Published
2021-03
Volume
9
Pages
100075
ISSN
2590-0986 (ISSN-L)
OpenAlex
W3107028140
Cited by
271
References
32
FWCI
23.20
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biologics vs. small molecules: Drug costs and patient access. https://app.cochat.ai/papers/10.1016/j.medidd.2020.100075
The paper
Makurvet, F. D. (2021). Biologics vs. small molecules: Drug costs and patient access. Medicine in Drug Discovery. https://doi.org/10.1016/j.medidd.2020.100075

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.